Skip to main content
Sun Pharma Advanced Research Company Ltd. logo

Sun Pharma Advanced Research Company Ltd. — Investor Relations & Filings

Ticker · SPARC ISIN · INE232I01014 LEI · 3358001Y3QHHUNROTJ51 BSE.NS Professional, scientific and technical activities
Open in API
Filings indexed 638 across all filing types
Latest filing 2024-09-25 Regulatory Filings
Country IN India
Listing BSE.NS SPARC

About Sun Pharma Advanced Research Company Ltd.

https://www.sparc.life

Sun Pharma Advanced Research Company Ltd. (SPARC) is a clinical-stage biopharmaceutical company dedicated to the research and development of innovative pharmaceutical products and drug delivery systems. SPARC focuses on creating new chemical entities (NCEs), new biological entities (NBEs), and reformulated products that address significant unmet medical needs. The company utilizes proprietary technology platforms, such as WrapMatrix and Nanotecton, to enhance the efficacy and safety of treatments. Its research pipeline primarily targets therapeutic areas including oncology, neurodegeneration, and ophthalmology. SPARC advances candidates through various stages of clinical trials to provide value-added medicines and novel therapeutic solutions for complex health conditions, leveraging its expertise in formulation and clinical development to improve patient outcomes globally.

Recent filings

Filing Released Lang Actions
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal notification from the company to stock exchanges about the closure of the trading window for insiders ahead of the announcement of the company's unaudited financial results for the second quarter and half year ended September 30, 2024. It references compliance with SEBI regulations and the company's code of conduct for insider trading. The document does not contain any financial data or results itself, nor does it present a report or detailed financial analysis. It is an announcement related to trading restrictions prior to the release of financial results. Given the short length (1589 characters) and the nature of the content, this fits best as a Regulatory Filing (RNS) rather than an Interim Report (IR) or Earnings Release (ER).
2024-09-25 English
Shareholders meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an official communication addressed to stock exchanges regarding the voting results of the 19th Annual General Meeting (AGM) held on August 12, 2024. It includes detailed voting results for multiple resolutions, attendance particulars, and the Scrutinizer's Consolidated Report. The content focuses on the outcome of shareholder votes on various agenda items such as adoption of financial statements, director appointments, and fund raising approvals. There is no presentation material, transcript of discussions, or full financial statements included. The document is a formal announcement of the voting results following the AGM, consistent with the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The length and detail confirm it is not a brief report publication announcement or a simple regulatory filing. Therefore, the correct classification is DVA with high confidence.
2024-08-14 English
Shareholders meeting
AGM Information Classification · 100% confidence The document is a detailed communication addressed to stock exchanges regarding the outcome of the 19th Annual General Meeting (AGM) of Sun Pharma Advanced Research Company Ltd. It includes the proceedings of the AGM, the Chairman's speech, and details about voting and resolutions passed. The content focuses on the AGM event itself, including business transacted, voting procedures, and speeches, rather than presenting a full annual report or financial statements. The document length is substantial (15,000 characters), and it contains the actual proceedings and speech text, not just an announcement or a brief summary. Therefore, it fits the category of AGM Information (AGM-R) as it provides materials shared during the AGM, including the Chairman's speech and meeting proceedings.
2024-08-12 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a disclosure under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which involves publishing an extract of financial results for the first quarter ended June 30, 2024. It includes newspaper clippings of the financial results and mentions that these are also available on the company's website. The document is a formal announcement to stock exchanges about the publication of the financial results extract, not the full financial report itself. The length is about 15,000 characters, but the content is primarily an announcement with attached newspaper advertisements, not the detailed financial statements or management discussion. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement of financial results publication, not the full interim or quarterly report itself.
2024-08-06 English
Financial Result Updates
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement from Sun Pharma Advanced Research Company Limited dated August 5, 2024, regarding the approval and disclosure of unaudited standalone and consolidated financial results for the first quarter ended June 30, 2024. It includes a Limited Review Report by the statutory auditors, detailed financial tables with income, expenses, profit/loss, and notes explaining the results and accounting standards applied. The presence of comprehensive financial data for a quarter, auditor's review, and management approval indicates this is a quarterly financial report. The document is about interim financial results, not a full annual report or just an announcement of a report. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2024-08-05 English
Statement of deviation(s) or variation(s) under Reg. 32
Capital/Financing Update Classification · 95% confidence The document is a formal communication addressed to stock exchanges regarding the statement on deviation or variation in the use of proceeds from a Preferential Issue. It references SEBI regulations and confirms that there is no deviation or variation in the use of proceeds as per the original objects stated in the relevant resolutions and offer letters. The document includes a statement reviewed and approved by the Audit Committee, detailing the use of funds raised through the Preferential Issue. It is a compliance disclosure related to the use of funds from a capital raising event, not a full financial report or earnings release. The content aligns with updates on capital raising and use of proceeds, which fits the category of Capital/Financing Update (CAP). The document is about the use of proceeds from a preferential issue and confirms no deviation, which is typical for capital/financing updates under SEBI regulations.
2024-08-05 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.